AHA Scientific Sessions 2023 Late-Breaking Science Coverage

Published: 30 October 2023

  • Views:

    Views Icon 2000
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Stay up-to-date with the latest data in cardiovascular science with the help of renowned experts and emerging voices who offer concise summaries, in-depth discussions, and critical reviews to keep you informed.

 

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. With their keen awareness of cardiovascular innovation, they offer concise perspectives on late-breaking data.

 

Dr Harriette Van Spall returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

 

Watch our Expert interviews for late-breaking science methodology, results and implications for practice and research in under 10 minutes.

 

Delve into the personal motivations of some of the investigators, and gain valuable insights and advice for early career researchers in our Behind the Heart series. These short videos offer an opportunity to look beyond scientific achievements and connect on a more personal level.

More from this programme

Part 1

View from the Thoraxcenter

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. 

Part 2

Late-Breaker Discussions with Harriette Van Spall

Dr Harriette Van Spall, recipient of 2022's AHA Dr. Nanette K. Wenger Award, returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

About the episode

AHA 2023 — Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) sat down with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the SELECT trial (NCT03574597).

In this randomized, double-blind, parallel-group, placebo-controlled trial sponsored by Novo Nordisk, semaglutide was compared with a placebo in patients who have overweight or obesity and a history of cardiovascular disease. A total of 17,609 participants were enrolled by the investigators. In the investigator arm, participants received semaglutide injections as an adjunct to standard-of-care. The primary endpoint of this trial is the time to the first occurrence of a composite endpoint, which includes cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.

Recorded on-site at AHA Scientific Sessions 2023, Philadelphia. 

Support: This is an independent discussion produced by Radcliffe Cardiology.

Editor: Mirjam Boros, Jordan Rance
Videographers: Dan Brent, Mike Knight

Faculty Biographies

A Michael Lincoff

A Michael Lincoff

Dr A. Michael Lincoff, MD, assumes the role of Vice Chairman within the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, acting as an interventional cardiologist at the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic.

With a purview extending beyond clinical practice, Dr Lincoff spearheads clinical research endeavours throughout the Cleveland Clinic as the Director of the Center for Clinical Research at the Lerner Research Institute. He is also at the helm of the Cleveland Clinic Coordinating Center for Clinical Research (C5Research), an academic research organization dedicated to planning, coordinating, and managing multicenter clinical trials exploring new pharmacologic or device therapies.

Dr Lincoff's research endeavours are concentrated on advancing therapies aimed at mitigating acute and long-term complications of percutaneous coronary revascularization procedures. Additionally, his work seeks to…

View full profile
Harriette Van Spall

Harriette Van Spall

Associate Professor of Medicine, Director of E-Health and Virtual Care

Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.

She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.

Dr Van Spall is an Editorial Board…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.